Answers are grounded in this paper and cite their sources.
Keloids are pathological scars characterized by abnormal fibroblast activation and excessive extracellular matrix (ECM) deposition during wound healing, resulting in persistent fibrotic remodeling. Effective in vitro models with both biomimicry and reproducibility remain lacking. Here, we established a membrane-based microfluidic skin-on-chip (SoC) platform supporting a three-dimensional full-thickness skin model. By integrating patient-derived keloid fibroblasts, tunable ECM stiffness, and transforming growth factor-beta 1 (TGF-β1) stimulation, we developed a keloid-like fibrotic SoC model. The platform incorporated a high-stiffness hydrogel matrix to mimic the pathological mechanical properties associated with keloid fibrosis. The engineered model reproduced several key keloid-associated fibrotic characteristics, including increased collagen deposition, enhanced α-smooth muscle actin expression, elevated type I/III collagen ratio, and fibrosis-related transcriptional changes. Drug evaluation further demonstrated that nintedanib and 5-fluorouracil attenuated fibrosis-related phenotypes and reduced profibrotic gene expression. In summary, we present an engineered keloid-like fibrotic SoC platform that integrates pathological mechanical and biochemical cues, providing an engineered platform for investigating keloid-associated fibrotic remodeling and evaluating potential antifibrotic interventions.
No takes yet. Share an insight, caveat, or question.
Si et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: